Avoiding Bias in the Conduct and Reporting of Cost-Effectiveness Research Sponsored by Pharmaceutical Companies
Hillman, Alan L.
Eisenberg, John M.
Pauly, Mark V.
New England Journal of Medicine. 1991 May 9; 324(19): 1362-1365.
As focus grows on containing health care costs, companies are eager to demonstrate the cost-effectiveness of their products. Hillman explores the relationship between the pharmaceutical industry and academia in industry-sponsored economic analysis, relating examples of potential bias in research, and approaching the question of regulation of economic analysis. He points out that unlike clinical trials, economic analyses involve subjective criteria, use unstandardized, selective, and variable data, and are overseen by marketing divisions, not scientific ones. Pressure on researchers to produce favorable findings is applied by the pharmaceutical industry, peers, editors, and academic institutions. Hillman suggests an eight-point standard protocol for economic analysis which aims at minimizing bias in the relationship between industry and investigators. (KIE abstract)
Advertising; Biomedical Research; Clinical Trials; Conflict of Interest; Drug Industry; Drugs; Economics; Evaluation; Evaluation Studies; Financial Support; Food; Government; Government Regulation; Health; Health Care; Industry; Investigators; Marketing; Patient Care; Pharmaceutical Industry; Regulation; Research; Research Design; Researchers; Reporting; Social Sciences; Standards; Universities;
Showing items related by title, author, creator and subject.
Avoiding Bias in the Conduct and Reporting of Cost- Effectiveness Research Sponsored by Pharmaceutical Companies Hillman, Alan L.; Eisenberg, John M.; Pauly, Mark V.; Bloom, Bernard S., (1991-05-09)